|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||19.20 - 20.39|
|52 Week Range||8.31 - 22.81|
|PE Ratio (TTM)||5.03|
|Forward Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|
LAVAL, Quebec, Dec. 15, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (VRX) (VRX) ("Valeant") announced today the results to date of the pending cash tender offers (the "Tender Offers") by Valeant and Valeant Pharmaceuticals International ("VPI," and together with Valeant, the "Offerors"), a wholly-owned subsidiary of Valeant, to purchase up to $1,500,000,000 aggregate principal amount (the "Aggregate Maximum Purchase Amount") of their respective outstanding notes listed in the table below (collectively, the "Notes"), as well as the anticipated early settlement date for the Tender Offers on December 18, 2017 (the "Early Settlement Date"). Valeant is the Offeror for the notes issued by it, and VPI is the Offeror for the notes issued by it.
Valeant And One Of Its Subsidiaries Announce Early Tender Results And Early Settlement Date For Cash Tender Offers For Senior Notes
Shares of Valeant Pharmaceuticals International (VRX) are higher on Friday, recovering from a downgrade from JPMorgan yesterday, but investors shouldn't get too comfortable, warns Mizuho Securities. Analyst Irina Koffler reiterated an Underperform rating on the stock today, although she did raise he price target from $7 to $10. Koffler writes that while 2018 EBITDA guidance may not be "that disappointing," but she's not willing to abandon her bear thesis ahead of it.
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) almost shook off a bear from its tail amid some impressive turnaround efforts to "deftly" refinance debt. Mizuho analyst Irina Rivkind Koffler all the same does look for a "negative" reaction to the comeback stock of the Street in terms of the 2018 guide and underscores fears of a dilutive financing event, especially considering the latest rally.
NEW YORK, NY / ACCESSWIRE / December 15, 2017 / Progress of the recent tax bill hit a snag on Thursday as two GOP Senators raised some concerns. All sectors closed down on Thursday dragging markets lower, ...
U.S. equities fell on Thursday amid doubts over the fate of the GOP’s tax cut plans. The doubt hit investors after a number of Republican senators expressed reservations about the amount of the child tax credit. In the end, the Dow Jones Industrial Average lost 0.3%, the S&P 500 lost 0.4%, the Nasdaq Composite lost 0.3% and the Russell 2000 lost 1.2%.
Everything's been going so well for Valeant Pharmaceuticals International (VRX). See, Valeant has been on quite a run. Since bottoming at $8.51 in April, Valeant's shares have rallied more than 130% as the beleaguered pharmaceutical company sold off assets, and paid down or extended its debt.
Have Valeant Pharmaceuticals Intl Inc (NYSE:VRX) shares just gotten too expensive? Shares are tumbling 10% after a cautious analyst decided it is no longer wise to play it safe, deciding to step away from the sidelines on VRX. The reason? The struggling biotech giant's estimates for the next two years seem too ambitious. Moreover, now after shares have rallied close to 100% from the stock price before the third quarter print, Valeant's valuation simply does not make a "compelling" argument to invest.
In February 2017, the FDA (Food and Drug Administration) approved Valeant Pharmaceuticals' (VRX) Siliq injection for the treatment of adults with moderate to severe plaque psoriasis.
Disney (DIS) is spending $52 billion for most of 21st Century Fox’s (FOXA) film and TV assets. Disney shares are up over 2% on the deal news. Disney will also take on about $13 billion in debt.
As far as Jim Chanos is concerned, his hedge fund is different than most. Kynikos investments come not from the budding minds of rookies but from the time-tested partners, themselves. That’s because “the ...
Shares of Valeant Pharmaceuticals International Inc. dropped 4.3% in premarket trade Thursday, after the drug maker was downgraded at J.P. Morgan, which cited valuation and concerns over patent losses ...
On today's edition of PreMarket Prep, we're discussing the market's reaction to the Twenty-First Century Fox Inc (NYSE: FOXA ) deal with Walt Disney Co (NYSE: DIS ), Pier 1 Imports Inc (NYSE: PIR ) earnings, ...
Shares of Valeant Pharmaceuticals (VRX) surged more than 2% higher on Wednesday morning, touching a new 52-week high in the process. As we approach the New Year, it is time to ask: is Valeant officially back?
Shares of Valeant Pharmaceuticals International (VRX) are higher Tuesday, and have easily outperformed this year, to the point that shorts may be throwing in the towel. Today, Cantor Fitzgerald's Louise Chen and her team write that the company has also seen the largest decrease in short interest in her coverage universe as of the end of November. The move comes as Valeant rose from less than $15 in mid-month to nearly $22 today.
Canada's main stock index rose on Tuesday, led by gains in drugmaker Valeant Pharmaceuticals and in the financial services sector. * At 10:18AM ET , the Toronto Stock Exchange's S&P/TSX composite index ...
U.S. stock futures are trending cautiously higher this morning, as focus remains on the Federal Reserve and the central bank’s interest rate policy. Against this backdrop, Dow Jones Industrial Average futures are up 0.18%, S&P 500 futures have added 0.10% and Nasdaq-100 futures are higher by 0.02%. Taking a closer look at Monday’s options activity, Tesla Inc (NASDAQ:TSLA) calls and puts were active as reports emerged that “hundreds” of Model 3s are now showing up at delivery centers.
Every day on PreMarket Prep, hosts Joel Elconin and Dennis Dick highlight over a dozen key morning movers to keep an eye on throughout the day. Below is a trade we thought is particularly hot today. Valeant ...